Daily Technical Summary Reports on Generic Drugs Stocks -- Adamas Pharma, Catalent, Diplomat Pharmacy, and Ironwood Pharma

Monday, May 7, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, May 7, 2018 /PRNewswire/ --

If you want a free Stock Review on ADMS, CTLT, DPLO, and IRWD sign up now at

www.wallstequities.com/registration. For today, WallStEquities.com shifts focus on Adamas Pharmaceuticals Inc. (NASDAQ: ADMS), Catalent Inc. (NYSE: CTLT), Diplomat Pharmacy Inc. (NYSE: DPLO), and Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD). According
to Research and Markets' report titled, "US Generic Drug Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2018-2023," the US Generic Drug market has witnessed a transformation over the last three decades. From less than 20% of the total prescriptions, generic drugs now account for the majority of the total prescriptions dispensed in the US. All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Adamas Pharmaceuticals

Emeryville, California headquartered Adamas Pharmaceuticals Inc.'s shares recorded a trading volume of 1.53 million shares last Friday, which was above their three months average volume of 1.00 million shares. The stock finished the trading session 0.77% lower at $29.53. The Company's shares have gained 22.28% in the last month and 69.62% over the past year. The stock is trading above its 50-day and 200-day moving averages by 13.43% and 11.80%, respectively. Furthermore, shares of Adamas Pharma, which discovers, develops, and sells therapies for chronic neurologic disorders, have a Relative Strength Index (RSI) of 65.58.  

On May 02nd, 2018, Adamas Pharma announced that Gregory T. Went, Ph.D., the Company's Founder, Chairman and CEO, is scheduled to present at the Deutsche Bank 43rd Annual Health Care Conference on May 08th, 2018, at 2:50 p.m. EDT. Additionally, Richard A. King, COO, is scheduled to present at the Bank of America Merrill Lynch 2018 Health Care Conference on May 16th, 2018, at 1:40 p.m. PDT. Get the full research report on ADMS for free by clicking below at: www.wallstequities.com/registration/?symbol=ADMS

Catalent

On Friday, Somerset, New Jersey headquartered Catalent Inc.'s stock ended the session 1.40% higher at $40.66. A total volume of 715,107 shares was traded. The Company's shares have gained 2.32% in the last month and 40.55% over the past year. The stock is trading 0.67% above its 200-day moving average. Moreover, shares of Catalent have an RSI of 47.86.  

On May 01st, 2018, Catalent announced its results for the quarter ended March 31st, 2018. Revenue for Q3 2018 was $627.9 million, net earnings were $19.0 million, and adjusted EBITDA was $139.0 million. As of March 31st, 2018, the Company had $2.8 billion in total debt, and $2.4 billion in total debt net of cash and short-term investments, which is in-line with the total debt and net debt as of December 31st, 2017. The free technical report on CTLT can be accessed at: www.wallstequities.com/registration/?symbol=CTLT

Diplomat Pharmacy

Flint, Michigan headquartered Diplomat Pharmacy Inc.'s stock ended the day 0.24% higher at $21.09 with a total trading volume of 494,998 shares. The Company's shares have gained 4.72% in the last month and 33.57% over the past year. The stock is trading 3.85% above its 200-day moving average. Additionally, shares of Diplomat Pharmacy, which operates as an independent specialty pharmacy in the US, have an RSI of 49.51.  

On May 01st, 2018, Diplomat Pharmacy announced that its executives will attend the 43rd Annual Deutsche Bank Health Care Conference in Boston. Interim CEO Jeff Park, President Joel Saban, and CFO Atul Kavthekar are scheduled to present at 12:50 p.m. ET on May 09th, 2018. A live, audio-only webcast of the presentation and related materials will be available under the investor relations section of the Company's website. Sign up for free on Wall St. Equities and claim the latest report on DPLO at: www.wallstequities.com/registration/?symbol=DPLO

Ironwood Pharmaceuticals

Shares in Cambridge, Massachusetts headquartered Ironwood Pharmaceuticals Inc. recorded a trading volume of 1.13 million shares. The stock ended Friday's session 1.31% higher at $18.59. The Company's shares have gained 25.69% in the last month, 36.99% over the previous three months, and 16.04% over the past year. The stock is trading above its 50-day and 200-day moving averages by 16.91% and 19.16%, respectively. Furthermore, shares of Ironwood Pharma have an RSI of 63.80.  

On May 02nd, 2018, Ironwood Pharma announced that it filed definitive proxy materials with the SEC in connection with the Company's Annual Meeting of Shareholders on May 31st, 2018. The Company's shareholders of record as of the close of business on April 06th, 2018 will be entitled to vote at the Annual Meeting. See the free research coverage on IRWD at: www.wallstequities.com/registration/?symbol=IRWD

--

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

 

Cision View original content:http://www.prnewswire.com/news-releases/daily-technical-summary-reports-on-generic-drugs-stocks----adamas-pharma-catalent-diplomat-pharmacy-and-ironwood-pharma-300643417.html

SOURCE Wall St. Equities



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store